“A Multi-Center, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children/Adolescents, 9-16 Years, with Primary Axillary Hyperhidrosis”, J of Skin, vol. 4, no. 6, p. s116, Oct. 2020, doi: 10.25251/skin.4.supp.116.